Novo Nordisk has partnered with Crux to expand access to anti-obesity medicines such as Wegovy for employer health plans in the United States. The collaboration focuses on simpler benefit designs and more predictable pricing for employer-sponsored coverage, targeting affordability and access barriers for GLP-1 obesity treatments for covered employees and dependents. The tie-up aims to make these treatments easier for employers to include in their health plans by using more transparent pricing and streamlined benefit structures. This development sits within the broader trend of rising employer and insurer interest in obesity treatments as a defined benefit category.
Novo Nordisk A/SPartnership with Crux expands Wegovy access for US employer health plans, boosting demand.
Crux partners with Novo Nordisk to facilitate employer health plan access to obesity drugs, increasing its service demand.